Merck (MRK) is preparing to spend nearly $6 billion in cash to acquire Terns Pharmaceuticals (TERN), a move that reads like a carefully scripted sequel to its Keytruda blockbuster rather than an impulsive spin-off. The price represents a premium to Terns’ roughly $5.3 billion market value and instantly shifts the biotech from speculative favorite to strategic asset on Big Pharma’s main stage.
Investors have taken note: reports of advanced deal talks sent Terns shares sharply higher in recent sessions, as the market did what it does best—discount the future before the ink is even dry. For Merck, the transaction underlines a simple truth: when a franchise as large as Keytruda edges toward a 2028 patent cliff, standing still is the riskiest position in the portfolio.
Why Terns Matters More Than Its Ticker
Terns is not a household name, but its pipeline reads like a curated collection of high-conviction themes in modern drug development. At the center sits TERN-701, a small-molecule treatment in early-stage trials for chronic myeloid leukemia (CML), positioned as a potential rival to Novartis’s (NVS) Scemblix in a field where physicians appreciate targeted, oral options.
Alongside oncology, Terns has quietly built out a slate of metabolic candidates, including GIPR modulators and oral GLP-1–focused programs targeting obesity and related liver diseases such as NASH/MASH. That dual focus on cancer and obesity puts the company squarely at the crossroads of two of the highest-value therapeutic markets in healthcare, an intersection where Big Pharma rarely drives slowly.
The Deal Logic: Hedge the Cliff, Buy the Optionality
The strategic rationale is as old as pharmaceutical patent law but updated for the GLP-1 era. Keytruda, Merck’s immuno-oncology juggernaut, remains a revenue machine, yet its 2028 patent expiry has turned every early-stage transaction into a line item under “life after Keytruda” on investor scorecards. By paying a roughly mid-teens premium for Terns, Merck is effectively purchasing an options package on future oncology and metabolic cash flows, rather than waiting to overpay later for later-stage assets.
Critics will point out that TERN-701 is still in Phase 1/2 and competing against an entrenched player, making the risk-reward profile closer to a well-hedged call option than a guaranteed coupon. Yet, for a company with more than $65 billion in revenue and robust profitability metrics, absorbing early-stage risk in exchange for long-duration upside fits neatly within Merck’s capital allocation playbook.
The Pipeline Inside the Pipeline
The real intrigue may sit beyond TERN-701, in how Merck integrates Terns’ metabolic franchise into its own R&D engine. Terns’ programs include an oral GLP-1 receptor agonist, GIPR modulators for obesity, and a THR-β agonist designed to improve NASH outcomes—each aimed at massive unmet-need markets currently dominated by injectables and a handful of large players.
If Merck can successfully pair its development and commercial scale with Terns’ early clinical data—especially around combinations such as GLP-1 plus GIPR modulation—it could secure a differentiated foothold in the next wave of obesity and metabolic therapies. In Wall Street terms, Merck is not just buying a pipeline; it is buying a set of future licensing conversations, pricing debates, and, potentially, a few very crowded conference-room breakout sessions.
What It Signals for Biotech M&A
For the broader biotech sector, the Terns transaction is another data point in a familiar but welcome pattern: when the patent cliffs loom, the M&A cycle tends to remember biotech’s phone number. A near-$6 billion all-cash deal for a company with largely early- and mid-stage assets sends a message that well-positioned platforms in oncology and obesity can command strategic multiples, even before late-stage readouts arrive.
That dynamic may embolden other emerging players with differentiated science and clean balance sheets to hold out for richer terms, while pushing large-cap pharmas to move earlier in the clinical curve to secure access. For investors, the takeaway is that the next phase of this cycle may reward those willing to underwrite clinical risk long before the first offer letter shows up—provided they can stomach a bit of volatility along the way.
The Sources
[1] Merck nears $6 bln deal for Terns Pharma, FT reports https://investing.com/news/stock-market-news/merck-nears-6-bln-deal-for-terns-pharma-ft-reports-4578984?ampMode=1
[2] Merck (MRK) Nears $6 Billion Acquisition of Terns Pharmaceutical https://www.gurufocus.com/news/8740894/merck-mrk-nears-6-billion-acquisition-of-terns-pharmaceuticals-tern
[3] Merck nears $6bn biotech deal to boost cancer drug pipeline https://www.ft.com/content/3f695210-8cc0-4736-837a-7961d80588d9
[4] Merck Nears $6 Billion Deal to Boost Drug Pipeline, FT Says (1) https://news.bloomberglaw.com/pharma-and-life-sciences/merck-nears-6-billion-deal-to-boost-drug-pipeline-ft-says-1
[5] Merck Nears $6 Billion Acquisition of Terns Pharma to Boost Cancer … https://money.usnews.com/investing/news/articles/2026-03-24/merck-nears-6-billion-all-cash-deal-to-buy-terns-pharma-ft-reports
[6] The Wall Street Journal – Breaking News, Business, Financial & Economic News, World News and Video https://www.wsj.com
[7] Pipeline – Terns Pharma https://www.ternspharma.com/pipeline/
[8] Merck’s Terns Buy: A Pipeline Hedge or a Premature Premium? https://www.ainvest.com/news/merck-terns-buy-pipeline-hedge-premature-premium-2603/
[9] Pipeline – Terns Pharmaceuticals https://terns-staging.squarespace.com/pipeline
[10] Terns Pharma ‘builds upon pipeline’ of NASH, obesity research https://flgastro.org/video-terns-pharma-builds-upon-pipeline-of-nash-obesity-research/
[11] Merck’s All-Cash Deal to Value Terns at $6 Billion, Financial Times … https://www.binance.com/en-TR/square/post/305191174874178
[12] Merck nears $6 billion acquisition of Terns Pharma to boost cancer … https://www.investing.com/news/stock-market-news/merck-nears-6-billion-allcash-deal-to-buy-terns-pharma-ft-reports-4578962
[13] Merck Nears Deal to Buy Acquire Terns Pharmaceuticals – Bloomberg https://www.bloomberg.com/news/articles/2026-03-25/merck-nears-deal-to-buy-acquire-terns-pharmaceuticals
[14] Finance and Markets https://www.wsj.com/finance
[15] How to Write Headlines Like The Wall Street Journal https://raganconsulting.com/5-tips-to-write-headlines-from-the-wall-street-journal/
